## ABBV: AbbVie Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.8% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($212.76)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Jump Financial LLC Buys New Shares in AbbVie Inc. $ABBV**
- Source: MarketBeat | 20251208T114452 | Bullish | Relevance: 100%
-  Jump Financial LLC has acquired a new stake in AbbVie Inc. (NYSE:ABBV) by purchasing 84,789 shares valued at approximately $15,739,000 during the second quarter. Other institutional investors also increased their holdings in AbbVie, which reported strong quarterly earnings and increased its dividend. The company also received several positive analyst ratings and price target increases.

**2. Ose Immunotherapeutics stock falls after AbbVie deal amendment By Investing.com**
- Source: Investing.com UK | 20251208T131948 | Neutral | Relevance: 99%
- Ose Immunotherapeutics' stock dropped 4.25% after amending its agreement with AbbVie, shifting more financial and developmental responsibility to Ose. Under the revised terms, Ose will now fund and conduct the Phase 1 study for their immunotherapy partnership, eliminating a previously anticipated milestone payment. While the overall deal value remains unchanged at $700 million, the market reacted negatively to Ose's increased financial burden and the removal of near-term payment certainty.

**3. Daiwa Securities Group Inc. Buys 38,862 Shares of AbbVie Inc. $ABBV**
- Source: MarketBeat | 20251209T103049 | Bullish | Relevance: 99%
-  Daiwa Securities Group Inc. increased its stake in AbbVie Inc. by 14.2% during the second quarter, now owning 312,361 shares valued at $57.98 million. Several other institutional investors also adjusted their positions in ABBV, which maintains a "Moderate Buy" rating from analysts with an average target price of $241.85. AbbVie recently reported strong quarterly earnings, exceeding analyst estimates, and increased its quarterly dividend.

**4. 1832 Asset Management L.P. Increases Stock Position in AbbVie Inc. $ABBV**
- Source: MarketBeat | 20251206T170724 | Bullish | Relevance: 99%
- 1832 Asset Management L.P. significantly increased its stake in AbbVie Inc. (NYSE:ABBV) by 158.7% in Q2 2025, now holding 20,590 shares valued at approximately $3.82 million. Other institutional investors like Norges Bank and Nuveen LLC also established substantial new positions. AbbVie reported strong Q3 earnings, beating EPS estimates, with revenue up 9.1% year-over-year, and raised its quarterly dividend.

**5. California Public Employees Retirement System Sells 778,732 Shares of AbbVie Inc. $ABBV**
- Source: MarketBeat | 20251207T090752 | Somewhat-Bullish | Relevance: 99%
- The California Public Employees Retirement System (CalPERS) significantly reduced its stake in AbbVie Inc. (NYSE:ABBV) by 13.7%, selling 778,732 shares in Q2 and now holding 4,890,752 shares valued at approximately $907.8 million. This makes AbbVie its 24th largest position, accounting for 0.28% of the fund's holdings. The article also highlights AbbVie's strong Q3 earnings beat, increased quarterly dividend, and a consensus "Moderate Buy" rating from analysts.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 3 ($0.06M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.1% (+0.2%)
- Blackrock Inc.: 8.3% (-1.0%)
- JPMORGAN CHASE & CO: 6.4% (+97.6%)
- State Street Corpora: 4.5% (-0.2%)
- Morgan Stanley: 2.4% (-0.1%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.42 indicates undervaluation relative to growth. Forward P/E 15.7x attractive for 34% earnings growth. Quality metrics strong (ROE 138%). Balance sheet: $6.5B free cash flow. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $394.3B |
| Beta | 0.35 |
| 52W Range | $164.39 - $244.81 |
| Short Interest | 1.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.42 |
| Forward P/E | 15.7 |
| Current P/E | 21.0 |
| YoY Growth | 33.9% |
| EPS Direction | FALLING |

### Technicals

MRS_10 strengthening from -4.8% to -2.8% (+2.0% in 5 days), confirming momentum buildup. Below STRENGTH zone by 5.8pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.09x) but short-term weakness (below SMA20). MACD histogram bearish (-0.77), momentum weakening. RSI neutral at 44.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.83% (CS: 24) | Weak |
| RSI_14 | 44.2 | Neutral |
| MACD Histogram | -0.77 | Bearish |
| vs SMA20 | 0.974x | Below |
| vs SMA50 | 0.978x | Below |
| vs SMA200 | 1.090x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $223.12
- **Stop Loss:** $212.76 (4.6% risk)
- **Target:** $233.48 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 48
- **Position Value:** $10,709.76
- **Portfolio %:** 10.71%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-06 (Est: $3.35)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.78 | $1.86 | +4.2% |
| 2025Q2 | $2.91 | $2.97 | +2.1% |
| 2025Q1 | $2.40 | $2.46 | +2.6% |
| 2024Q4 | $2.12 | $2.16 | +1.9% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*